Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press73610.17650/2949-5857-2024-14-3-27-34ORIGINAL REPORTОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕPrognostic value of the BAP1 gene expression level in patients with clear cell renal cell carcinomaПрогностическое значение уровня экспрессии гена BAP1 у больных светлоклеточным почечно-клеточным ракомhttps://orcid.org/0000-0002-5734-7318TsedenovaK. O.ЦеденоваК. О.
Russian Federation

Kermen Olegovna Tsedenova 

5 Vtoroy Botkinskiy proezd, Moscow 125284

Кермен Олеговна Цеденова 

125284 Москва, 2-й Боткинский проезд, 5

k.o.tsedenova@gmail.comhttps://orcid.org/0000-0001-7748-9527MatveevV. B.МатвеевВ. Б.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522

115522 Москва, Каширское шоссе, 24

https://orcid.org/0000-0001-7336-9210BezhanovaS. D.БежановаС. Д.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522

115522 Москва, Каширское шоссе, 24

https://orcid.org/0000-0002-2824-3704ZaridzeD. G.ЗаридзеД. Г.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522

115522 Москва, Каширское шоссе, 24

https://orcid.org/0000-0003-4744-6141KononetsP. V.КононецП. В.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522

115522 Москва, Каширское шоссе, 24

S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center, Moscow Healthcare DepartmentГБУЗ г. Москвы «Московский многопрофильный научно-клинический центр им. С.П. Боткина Департамента здравоохранения г. Москвы»N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России1209202414327341209202412092024Copyright ©; 2024, ABV-pressCopyright ©; 2024, АБВ-пресс2024ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/736

Introduction. There is a lack of evidence of BAP1 expression on patient prognosis, that indicates the need for further study of this topic.

Aim. To evaluate BAP1 expression level in clear cell kidney cancer patients.

Materials and methods. We included in a retrospective study based on N.N. Blokhin National Medical Research Center of Oncology database from 2009 to 2013 patients with clear cell kidney cancer, who were divided into 2 groups depending on BAP1 status. Primary endpoints were BAP1 expression level, 5-year overall survival (OS), disease-free survival (DFS) and cancer-specific survival (CSS).

Results. 40 patients were included in the BAP1+ group, 53 patients – in the BAP1– group. There were no statistically significant differences in parameters that could affect the prognosis between our groups. 5-year OS was higher in the BAP1+ group (76.0 %) compared to BAP1– (58.0 %) (p = 0.040). There were no statistically significant differences between 5-year DFS and CSS.

Conclusions. BAP1+ patients had significantly higher OS, but BAP1 mutation didn’t affect DFS and CSS.

Введение. существует недостаточно данных о влиянии уровня экспрессии гена BAP1 на прогноз пациентов, что говорит о необходимости дальнейшего изучения этой темы.

Цель исследования – оценка прогностического значения уровня экспрессии ВАР1 у больных светлоклеточным раком почки.

Материалы и методы. В ретроспективное исследование на основе базы данных НМИЦ онкологии им. Н.Н. блохина за период 2009–2013 гг. включены пациенты со светлоклеточным почечно-клеточным раком, разделенные на 2 группы в зависимости от статуса BAP1. Основные оцениваемые параметры: уровень экспрессии гена BAP1, 5-летняя общая (ОВ), безрецидивная (бРВ) и опухолеспецифическая (ОсВ) выживаемость.

Результаты. В группу BAP1+ включено 40 пациентов, группу BAP1– составили 53 пациента. достоверных различий по параметрам, способным влиять на прогноз, между исследуемыми группами не зафиксировано, 5-летняя ОВ была выше в группе BAP1+ (76,0 %) в сравнении с группой BAP1– (58,0 %) (р = 0,040). достоверных различий 5-летней бРВ и ОсВ не отмечено.

Выводы. у пациентов с мутацией ВАР1 отмечены достоверно более высокие показатели ОВ, но мутация ВАР не показала статистически значимого влияния на бРВ и ОсВ.

clear cell kidney cancerBAP1светлоклеточный почечно-клеточный ракген ВАР11. Hsieh J.J., Purdue M.P., Signoretti S. et al. Renal cell carcinoma. Nat Rev Dis Primers 2017;3:17009. DOI: 10.1038/nrdp.2017.9Hsieh J.J., Purdue M.P., Signoretti S. et al. Renal cell carcinoma. Nat Rev Dis Primers 2017;3:17009. DOI: 10.1038/nrdp.2017.92. Maher E.R. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol 2018;36(12):1891–8. DOI: 10.1007/s00345-018-2288-5Maher E.R. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol 2018;36(12):1891–8. DOI: 10.1007/s00345-018-2288-53. Jensen D.E., Proctor M., Marquis S.T. et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16(9):1097–112. DOI: 10.1038/sj.onc.1201861Jensen D.E., Proctor M., Marquis S.T. et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16(9):1097–112. DOI: 10.1038/sj.onc.12018614. Wang A., Papneja A., Hyrcza M. et al. Gene of the month: BAP1. J Clin Pathol 2016;69(9):750–3. DOI: 10.1136/jclinpath-2016-203866Wang A., Papneja A., Hyrcza M. et al. Gene of the month: BAP1. J Clin Pathol 2016;69(9):750–3. DOI: 10.1136/jclinpath-2016-2038665. Louie B.H., Kurzrock R. BAP1: Not just a BRCA1-associated protein. Cancer Treat Rev 2020;90:102091. DOI: 10.1016/j.ctrv.2020.102091Louie B.H., Kurzrock R. BAP1: Not just a BRCA1-associated protein. Cancer Treat Rev 2020;90:102091. DOI: 10.1016/j.ctrv.2020.1020916. Welchman R.L., Gordon C., Mayer R.J. Ubiquitin and ubiquitinlike proteins as multifunctional signals. Nat Rev Mol Cell Biol 2005;6(8):599–609. DOI: 10.1038/nrm1700Welchman R.L., Gordon C., Mayer R.J. Ubiquitin and ubiquitinlike proteins as multifunctional signals. Nat Rev Mol Cell Biol 2005;6(8):599–609. DOI: 10.1038/nrm17007. Nishikawa H., Wu W., Koike A. et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res 2009;69(1):111–9. DOI: 10.1158/0008-5472.CAN-08-3355Nishikawa H., Wu W., Koike A. et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res 2009;69(1):111–9. DOI: 10.1158/0008-5472.CAN-08-33558. Machida Y.J., Machida Y., Vashisht A.A. et al. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 2009;284(49):34179–88. DOI: 10.1074/jbc.M109.046755Machida Y.J., Machida Y., Vashisht A.A. et al. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 2009;284(49):34179–88. DOI: 10.1074/jbc.M109.0467559. Yu H., Mashtalir N., Daou S. et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol 2010;30(21):5071–85. DOI: 10.1128/MCB.00396-10Yu H., Mashtalir N., Daou S. et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol 2010;30(21):5071–85. DOI: 10.1128/MCB.00396-1010. Bononi A., Giorgi C., Patergnani S. et al. BAP1 regulates IP3 R3 -mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature 2017;546(7659):549–53. DOI: 10.1038/nature22798Bononi A., Giorgi C., Patergnani S. et al. BAP1 regulates IP3 R3 -mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature 2017;546(7659):549–53. DOI: 10.1038/nature2279811. Zhang Y., Shi J., Liu X. et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 2018;20(10):1181–92. DOI: 10.1038/s41556-018-0178-0Zhang Y., Shi J., Liu X. et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 2018;20(10):1181–92. DOI: 10.1038/s41556-018-0178-012. Cheung M., Kadariya Y., Talarchek J. et al. Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. Cancer Lett 2015;369(2):261–5. DOI: 10.1016/j.canlet.2015.09.011Cheung M., Kadariya Y., Talarchek J. et al. Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. Cancer Lett 2015;369(2):261–5. DOI: 10.1016/j.canlet.2015.09.01113. Haugh A.M., Njauw C.N., Bubley J.A. et al. Genotypic and phenotypic features of BAP1 cancer syndrome: A report of 8 new families and review of cases in the literature. JAMA Dermatol 2017;153(10):999–1006. DOI: 10.1001/jamadermatol.2017.2330Haugh A.M., Njauw C.N., Bubley J.A. et al. Genotypic and phenotypic features of BAP1 cancer syndrome: A report of 8 new families and review of cases in the literature. JAMA Dermatol 2017;153(10):999–1006. DOI: 10.1001/jamadermatol.2017.233014. Jin S., Wu J., Zhu Y. et al. Comprehensive analysis of BAP1 somatic mutation in clear cell renal cell carcinoma to explore potential mechanisms in silico. J Cancer 2018;9(22):4108–16. DOI: 10.7150/jca.27281Jin S., Wu J., Zhu Y. et al. Comprehensive analysis of BAP1 somatic mutation in clear cell renal cell carcinoma to explore potential mechanisms in silico. J Cancer 2018;9(22):4108–16. DOI: 10.7150/jca.2728115. Joseph R.W., Kapur P., Serie D.J. et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 2014;120(7):1059–67. DOI: 10.1002/cncr.28521Joseph R.W., Kapur P., Serie D.J. et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 2014;120(7):1059–67. DOI: 10.1002/cncr.2852116. Gallan A.J., Parilla M., Segal J. et al. BAP1-mutated clear cell renal cell carcinoma. Am J Clin Pathol 2021;155(5):71828. DOI: 10.1093/ajcp/aqaa176Gallan A.J., Parilla M., Segal J. et al. BAP1-mutated clear cell renal cell carcinoma. Am J Clin Pathol 2021;155(5):71828. DOI: 10.1093/ajcp/aqaa17617. Fatima A., Mushtaq S., Loya A. et al. Expression of BAP1 in clear cell renal cell carcinoma. J Ayub Med Coll Abbottabad 2022;34(2):283–7. DOI: 10.55519/JAMC-02-9313Fatima A., Mushtaq S., Loya A. et al. Expression of BAP1 in clear cell renal cell carcinoma. J Ayub Med Coll Abbottabad 2022;34(2):283–7. DOI: 10.55519/JAMC-02-931318. Kapur P., Christie A., Raman J.D. et al. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. J Urol 2014;191(3): 603–10. DOI: 10.1016/j.juro.2013.09.041Kapur P., Christie A., Raman J.D. et al. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. J Urol 2014;191(3): 603–10. DOI: 10.1016/j.juro.2013.09.04119. Da Costa W.H., Fares A.F., Bezerra S.M. et al. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma. Urol Oncol 2019;37(1):78–85. DOI: 10.1016/j.urolonc.2018.10.017Da Costa W.H., Fares A.F., Bezerra S.M. et al. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma. Urol Oncol 2019;37(1):78–85. DOI: 10.1016/j.urolonc.2018.10.017